The following articles (labelled with PubMed ID or TBD) are for your review
PMID | Data | Article Title | Organization |
27839918 |
28 |
Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).![EBI](/images/logo_chembl.png) |
Takeda California |
27288183 |
130 |
Synthesis and biological evaluation of new [1,2,4]triazolo[4,3-a]pyridine derivatives as potential c-Met inhibitors.![EBI](/images/logo_chembl.png) |
Southeast University |
26762835 |
342 |
Discovery of 2-(1H-indol-5-ylamino)-6-(2,4-difluorophenylsulfonyl)-8-methylpyrido[2,3-d]pyrimidin-7(8H)-one (7ao) as a potent selective inhibitor of Polo like kinase 2 (PLK2).![EBI](/images/logo_chembl.png) |
Icahn School of Medicine At Mount Sinai |
23489211 |
44 |
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor.![EBI](/images/logo_chembl.png) |
Universit£ |
18183025 |
12060 |
A quantitative analysis of kinase inhibitor selectivity.![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
22014550 |
337 |
Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).![EBI](/images/logo_chembl.png) |
Ansaris |
22018461 |
41 |
Novel tricyclic inhibitors of IKK2: discovery and SAR leading to the identification of 2-methoxy-N-((6-(1-methyl-4-(methylamino)-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-7-yl)pyridin-2-yl)methyl)acetamide (BMS-066).![EBI](/images/logo_chembl.png) |
Bristol-Myers Squibb Research and Development |
22037378 |
31824 |
Comprehensive analysis of kinase inhibitor selectivity.![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
20961062 |
42 |
Indazolylpyrazolopyrimidine as highly potent B-Raf inhibitors with in vivo activity.![EBI](/images/logo_chembl.png) |
Pfizer |
19654408 |
2521 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).![EBI](/images/logo_chembl.png) |
Ambit Biosciences |
19788238 |
36 |
Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4).![EBI](/images/logo_chembl.png) |
University of Zurich |
19035792 |
85 |
Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.![EBI](/images/logo_chembl.png) |
Glaxosmithkline |
31757666 |
314 |
Discovery and optimization of heteroaryl piperazines as potent and selective PI3K? inhibitors.![EBI](/images/logo_chembl.png) |
Merck |
31693351 |
473 |
Discovery of 4![EBI](/images/logo_chembl.png) |
TBA |
30987781 |
88 |
Novel 7-formyl-naphthyridyl-ureas derivatives as potential selective FGFR4 inhibitors: Design, synthesis, and biological activity studies.![EBI](/images/logo_chembl.png) |
Southeast University |
30384048 |
365 |
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.![EBI](/images/logo_chembl.png) |
University of Florida |
31526603 |
379 |
Structure-based rational design of staurosporine-based fluorescent probe with broad-ranging kinase affinity for kinase panel application.![EBI](/images/logo_chembl.png) |
Takeda Pharmaceutical |